Other highlights in the March 3 issue of JNCI

Epithelial Cancer Risk Elevated in Hereditary Retinoblastoma Survivors

People who had hereditary retinoblastoma during childhood and did not receive high-dose radiation therapy to treat their cancer are nevertheless at an increased risk of epithelial cancers such as cancer of the esophagus, stomach, colon, lung, breast, cervix, or prostate.

Retinoblastoma is a rare childhood tumor of one or both eyes. The tumor can be sporadic or hereditary, the latter of which is associated in a mutation in the retinoblastoma 1 (RB1) gene. Compared with the general population, survivors of hereditary retinoblastoma have higher risks of early-onset second cancers, particularly sarcomas, brain tumors, and melanoma, and that risk is strongly associated with the amount of radiation received during retinoblastoma treatment. However, there is little information available about cancer risk later in life among retinoblastoma survivors--specifically, cancers that are likely not related to radiotherapy.

Olivia Fletcher and Julian Peto, of the London School of Hygiene and Tropical Medicine, and colleagues estimated the risks of the epithelial cancers that commonly occur after age 50 among 144 retinoblastoma survivors who were unlikely to have been treated with high-dose radiotherapy.

They found that very few of the cancers diagnosed within their cohort were bone or soft tissue cancers, in contrast to findings from contemporary studies in which patients are treated with radiotherapy and are more likely to have sarcomas as their second cancers. Compared with the general population, the retinoblastoma survivors were more likely to die of lung cancer, bladder cancer, and all other epithelial cancers combined.

Contact: Lindsay Wright, London School of Hygiene and Tropical Medicine, 207-927-2073, Lindsay.Wright@lshtm.ac.uk

Dietary Folate Intake May Be Associated With Reduced Risk of Ovarian Can

Contact: Katie Arnold
Journal of the National Cancer Institute

Page: 1 2 3 4 5

Related biology news :

1. Other highlights in the September 1 JNCI
2. Other highlights in the August 18 JNCI
3. Other highlights in the August 4 JNCI
4. Other highlights in the July 7 JNCI
5. Other highlights in the June 16 JNCI
6. Other Highlights in the June 2 JNCI
7. Other highlights in the May 19 JNCI
8. Other highlights in the May 5 JNCI
9. Other highlights of the March 17 issue of JNCI
10. Other highlights in the February 18 issue of JNCI
11. Other highlights in the February 4 issue of JNCI

Post Your Comments:

(Date:1/27/2020)... ... January 27, 2020 , ... On Thursday, February 20, ... Life Sciences, Reed Tech and Richard Castle, Global Account Manager Medical Device ... the procedure, other topics include EU MDR timing deadlines, best practices in creating and ...
(Date:1/24/2020)... ... January 24, 2020 , ... The Rockies Venture Club and ... support early-stage bioscience companies in the state. , “Colorado has a ... funding they need to innovate and grow. This program will mobilize capital ...
(Date:1/23/2020)... ... January 23, 2020 , ... GIOSTAR/HEAMGEN has developed ... cells. The red blood cells are made utilizing a bioreactor that permits ... therapy and replaces the need for a human blood donor. GIOSTAR/HEAMGEN ...
Breaking Biology News(10 mins):
(Date:2/21/2020)... ... February 20, 2020 , ... In a free session ... Synteract including Lisa Dilworth, BS, MS, Vice President Rare, Orphan and Pediatric ... feasible strategies and solutions to support patients, sites and sponsors. , When planning a ...
(Date:2/19/2020)... ... February 18, 2020 , ... Shoreline Biome, ... the strain level, recently unveiled a novel DNA isolation product. , Shoreline Rapid ... of high molecular weight (HMW) single-stranded DNA (ssDNA) in excess of 40 kB ...
(Date:2/11/2020)... ... February 11, 2020 , ... Synagro Technologies, ... America, today announced that the City of Fort Worth has partnered with Synagro ... Commencing in April of 2020, Synagro will assume operation of the city’s current ...
(Date:2/3/2020)... ... February 03, 2020 , ... Global ... announce that OmniType, the 11-locus, single tube multiplex successor to Holotype HLA is ... product featuring locus-multiplexing and short library preparation, for HLA genotyping from sample to ...
Breaking Biology Technology:
Cached News: